ABSTRACT-Linkage with records of the Connecticut Tumor Registry was used to determine cancer incidence in a cohort of workers (n=984) at a benzidine manufacturing facility. Compared to the findings for the Connecticut population, there was a statistically significant excess of bladder tumor among male cohort members [standardized incidence ratio (SIR) =343; 95% confidence limits (CL)=148, 676; n=830], which was confined to those with the highest estimated level of benzidine exposure (SIR= 1 ,303; CL=479, 2, 839; n=105). No significantly elevated risks were found for cancers at other anatomic sites in men or at any anatomic sites in women; nor was there any pattern of increasing risk with increasing benzidine exposure for sites other than bladder. In addition, the elevated bladder cancer risk was greater for men first employed during the earliest years of the plant, namely, 1945-49 (SIR=976; CL=262, 2,498) as compared to those first employed in 1950-54 (SIR=213; CL=3, 1,184) after equalization of duration of follow-up. These results suggest that the major preventive measures instituted around 1950 may have reduced bladder cancer risk in this plant.-JNCI 1986; 76:1-8.
The SUSpICIOn that exposure to dye intermediqtes, such as j3-naphthylamine and benzidine, might cause human bladder tumor was raised in the early 1900's after Rehn (1, 2) had reported an excess of bladder tumors among workers in the aniline dye industry. However, incomplete records and the fact that many workers were exposed to various chemicals made it impossible to identify any particular compound as the causative agent. By the 1930's it was clear from both experimental and epidemiologic evidence that j3-naphthylamine was a potent bladder carcinogen (3) (4) (5) . Subsequently, several epidemiologic studies supported a causal relationship between exposure to benzidine and the occurrence of bladder tumor (6) (7) (8) but uncertainty remained concerning the importance of the dose and the form of benzidine exposure (9) . Although substituted benzidines had been in production for [15] [16] [17] [18] [19] [20] years by the 1950's, there were not at that time any reports of bladd\r tumor associated with exposure to these chemicals.
In 1945, a chemical plant manufacturing benzidine and the substituted benzidines-dichlorobenzidine, dianisidine, and diorthotolidine (benzidine with Cl, O-CH3-,:and C1i3, respectively, substituted in the orthoposition)-set u~ operations in Connecticut. The company never manufactured j3-).1aphthylamine or any other recognized bladder carcino~en. In addition to having had potential exposure to the final manufactured products, employees at this plant could have had exposures to many raw materials: benzene, toluene, nitro-and chloro-substituted benzenes, strong acids, and chemicals produced at intermediate stages of processing. Production methods were designed to conform to the then cur-1 rent health and safety standards with respect to exposures to all potentially hazardous chemicals. Also, workers were instructed in work habits to minimize contact with finished products. Floors were washed frequently to remove spilled materials.
In 1948, this company asked the Dean of the Yale School of Medicine for help in exploring potential health risks at the plant and in recommending additional control procedures that might be indicated; one of us (J. W. M.) undertook to do so, and the manufacturer provided access to the plant and processes. Over the next few years, methods for biologic monitoring to detect diamines in the urine were developed and by 1950 were applied to workers in the plant (10) (11) (12) . Several important facts became apparent as a result. First, diamineproduction workers and maintenance men were generally excreting more amino compounds than were workers in other parts of the plant or those with other duties. Second, it was found that the amines were absorbed through the skin. Third, absorption was greater in hot, humid weather. As a result of these findings, simple control measures were devised to minimize contact, especially of the skin, with the amino com-ABBREVIATIONS USED: CL = 95% confidence limits; CTR = Connecticut Tumor Registry; ICD-O = International Classification of Diseases for Oncology; NOS = not otherwise specified; SIR = standardized incidence ratio(s); SRC=special reference committee; SSA=Social Security Administration.
2 Meigs, Marrett, Ulrich, et at pounds and were put into general use by about 1951. These included clean clothes, showers, and improved work practices. In addition, benzidine production was scheduled in cool weather when practicable (10, 11) . Continued monitoring permitted the management to identify workers with excess exposure and to recommend additional improvements in work practices. Despite lack of evidence for any risk associated with manufacture of the substituted benzidines, the company applied the same health hazard control methods to all diamine production. These measures resulted in a prompt reduction in worker exposure to diamines to about one third that of previous levels (10, 11) .
In addition to the above preventive measures, a bladder tumor early-detection program was begun, including periodic diagnostic procedures for all employees with exposure to diamines. Initially, annual cystoscopic examination of the urinary bladder was recommended, but some employees did not accept this procedure. In the late 1950's, when cytologic examination of the urine sediment for detection of neoplastic cells had become practicable, it replaced cystoscopy as the principal screening procedure. Working out of the plant's medical dispensary, an industrial nurse maintained records and scheduled cytology at regular intervals for the employees.
In 1962, the company underwent a change of ownership and the new owners decided, after a careful review, to discontinue production or handling of benzidine in 1965, although no reports of bladder tumors in workers exposed at this plant had been received by this time. Lack of evidence for human cancer risk from production of dichlorobenzidine, dianisidine, and diorthotolidine led to the decision to continue their manufacture, with increased efforts to minimize worker exposure.
In the mid-1970's a few cases of bladder tumor among employees were reported to the company. The management decided to try to reach every former employee, including laboratory and clerical staff, who had ever worked with benzidine, and offer him or her a diagnostic test (cytology) for bladder tumor. This program established the vital status of 574 (95%) of the 602 employees with any record of possible exposure to benzidine at the plant. The company also asked one of us (J. W. M.) not onJy to conduct an epidemiologic survey of the total work force-current and former, exposed and unexposed-to determine the size of the bladder tumor risk in relation to level of exposure and to preventive measures introduced in the early 1950's but also to evaluate other causes of mortality and cancer morbidity. The cohort for study included all employees who had worked at the plant at any time in the period 1945-65, during which benzidine as well as the three substituted benzidines were manufactured. This report presents the incident cancer experience of this cohort, through December 31, 1978, as determined by linkage with the records of the CTR. Results were analyzed with respect to level of exposure to benzidine, to duration of employment, and to period of first employment. The cohort's mortality experience will form the subject of a separate report.
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SUBJECTS AND METHODS
Cohort.-From company employment records, 997 men and women who had worked at the plant for at least 1 day during the years 1945-65 were identified. Company records generally included name; address (at time of employment); sex; Social Security number; dates of birth, hire, and termination; and limited job information. Thirteen cohort members (II men and 2 women) had to be eliminated due to lack of date of birth, which is essential for record linkage and for computation of expected numbers of tumors, leaving 984 subjects (830 males and 154 females) available for follow-up.
Exposure status.-The benzidine exposure status of each cohort member was determined on the basis of information contained in employment, production, and sales records. This information was reviewed by an SRC, which was comprised of management and long-term employees (former and current) familiar with both plant operations and the actual jobs performed by former employees. First, monthly benzidine production and sales records were compared with employment histo:r:ies, to determine maximum possible time of benzidine exposure for each employee. Those who had worked at the plant only during months when no benzidine was manufactured or handled were classified as unexposed. The SRC then reviewed all those potentially exposed, in most cases without knowledge of the medical status of the employee, particularly with respect to a diagnosis of bladder tumor. Collectively, the SRC could reconstruct reasonably detailed employment histories, particularly for those who had worked in the early years when the plant was small and record keeping limited and when the workers moved from task to task as needed. With the use of data from the production sales-employment record comparison regarding maximum potential time exposed to benzidine, employment histories (e.g., particular years worked, jobs held), and individual recall, the SRC attempted to determine the probable total duration of benzidine exposure for each worker. Details of exposure were not equally available for all subjects, and intensity of exposure varied substantially between persons and within persons over time. Hygienic measures adopted after 1949 were known to have reduced amine excretion in the work force (10, 11), but individual information was limited. The SRC used estimated amount of time exposed to benzidine (22 yr=high; 6 mo up to 2 yr=medium; 2 days up to 6 mo=low; 0-1 day=none) to create categories. These categories were more accurate indicators of benzidine exposure than length of employment but were not suitable for more precise quantitative use.
Cancer incidence, follow-up, and SIR.-Validity of the study depended on follow-up of employees and ascertainment of cancer incidence in Connecticut, with methods that minimized bias. The calculation of SIR required information for each subject as to his or her dates and total length of residence in Connecticut and any cancer diagnoses during this period.
Cancer incidence: Cancer ascertainment was through the CTR to which all newly diagnosed cancers in Connecticut residents have been reported by physicians, hospitals, and pathology laboratories for more than 40 years. For more than 10 years, systematic auditing of case ascertainment has been conducted by the staff of the CTR, as required by the National Cancer Institute's Surveillance, Epidemiology and End Results Program, of which the CTR is a part. Prior to the systematic audits. random audits were conducted. Ascertainment has been estimated to be more than 95% complete, at least since 1970 (Flannery JT: Personal communication). "Cancer" was defined by the CTR as any malignant growth except nonmelanotic skin cancer. In situ cancers were not included for analysis. Ascertainment of cancer among members of the cohort, either currently or previously employed, did not depend on records or activities of the company but was done· by the statewide system already described. The company's medical department referred employees, current or former, to their personal physicians if health status questions arose.
The names of all cohort members were computer linked with CTR records by the CTR staff. All cancer diagnoses that were reported to the CTR through the date that linkage was performed in 1981 were considered. CTR records for a given year are considered to be complete by about 2 years after the close of that year. The cut-off date of December 31, 1978, was used for statistical analysis. The linkage used name and date of birth or estimated year of birth for records where CTR had only age and year of diagnosis. Social Security number was not routinely recorded by the CTR until about 1979 and could be used rarely as a linkage variable. Possible matches were reviewed by hand and often required a search of paper files at the CTR to get exact name, birthdate, or other data to confirm or to refute the match. Only the first cancer diagnoses occurring between the dates of hire of the employees and the dates of last follow-ups were included for analysis. CTR records also included cancer stage and histology and occasionally smoking history. After cancer cases were ascertained through the CTR, the company's medical records of employees with cancer were searched for smoking histories.
Follow-up: The follow-up methods included linkages
Benzidine-Exposure Follow-up on Workers 3
with SSA records, Connecticut death certificates, and the Connecticut Department of Motor Vehicles' drivers' license files. Death certificates were sought for all those reported dead, to confirm fact and place of death. Additional follow-up depended on putative exposure status. Those with suspected exposure to benzidine were part of the company's urine cytology recall program. They were followed by regular and certified mail, with addresses based on company records, on personal information from other employees, and on linkage with motor vehicle license files of selected states outside Connecticut, with assistance from the Health Care Financing Administration of SSA. Other former employees and those exposed but not located in the recall program were followed as long as possible through Connecticut city directories, which cover about 92% of the population. Year of the last Connecticut residence so found, year of death in Connecticut, or December 31, 1978, whichever was earlier, was considered to be the date of last followup. Continuous Connecticut residence was assumed from time of employment to last known Connecticut address. Date of termination of employment was used where no further information could be found. Followup duration was established by these procedures for every cohort member. Ascertainment or nonascertainment of cancer did not influence determination of follow-up. SIR: A computer program developed by Monson (13) was used to calculate person-years at risk and observedto-expected ratios of cancer diagnoses by site, by latency, by period of first employment, by exposure level, and by duration of employment. For each subject, years-at-risk ceased at time of death (if it occurred in Connecticut), at tumor diagnosis, or with last known Connecticut residence, whichever came first. This program used ageand period of diagnosis-specific cancer incidence rates for the state of Connecticut for the period 1945-79, as prepared by Heston et al. (14) for computation of expected numbers. Results were given in terms of SIR, which were the observed-to-expected ratios multiplied by 100. CL for the SIR were computed on the assumption that the observed numbers of cancers follow the Poisson distribution. We decided only descriptive results were to be presented for females, since they numbered so few. 
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RESULTS
Among the 830 males, a total of 48 first pnmary cancers were reported to the CTR. Table 1 shows SIR for individual cancer sites with 3 or more observed cases; all others are included in the "other and unspecified" category. The SIR for all sites was 134 with CL of 99, 178. There were 8 bladder tumors, which represented a statistically significant excess (SIR, 343; CL, 148, 676). None of the remaining SIR were significantly different from 100. No cancer was reported to the CTR for any male after his last date of known Connecticut residence.
The details for 48 first primary cancers that were ascertained by the CTR among the 830 men are presented in table 2. Smoking histories were available for 21 of these: 7 from both company records and CTR files, with complete agreement on smoking status; 14 from CTR records only; and 7 from company records only . CTR records also mentioned alcohol intake in 2 cases. Table 2 shows that benzidine exposure was present in 7 (6 high, I medium) of 8 cases of bladder tumor and was absent in I. Of the 8, 3 were long-term cigarette smokers; the smoking histories of the other 5 were unknown. Six of the bladder tumor cases started work before 1950, when systematic hygiene measures began. The histologic types included 5 transitional cell carcinomas, NOS; 2 papillary transitional cell carcinomas; and 1 papillary carcinoma, NOS. All tumors were localized at the time of diagnosis except for the tumor in case #42, which was regional. Case #42 had worked in a building physically separated from the benzidine operation, with no record of benzidine exposure at any time, and could not be assumed to have a benzidine-related tumor. Among the 7 men with benzidine exposure, the time from first exposure at this plant to diagnosis averaged 20.9 years.
Cases #36 and #43 were referred to urologists for definitive diagnosis and subsequent reporting to the CTR, following company-sponsored urine cytology tests. It is unknown whether these subjects would have developed symptomatic bladder tumor within the period of study. The remaining cases were all symptomatic at time of diagnosis.
The median age at diagnosis of bladder tumor was 55 years old for the 7 men with benzidine exposure, compared to 68 years of age for all men reported to the CTR. However, younger median ages at diagnoses were also observed for the other major cancer sites, as would be expected in a cohort of men who had yet to attain the older ages at which most cancers occur.
Other cancer cases did not show the striking patterns of high benzidine exposure and early, prolonged employment that characterized the bladder tumor cases. Although lung cancer had an SIR of 150, 8 of the 11 subjects had records of heavy cigarette smoking, with no information for the other 3 .
Second primary cancers occurred in 2 men. Case #1 had a squamous carcinoma of the tonsil, NOS, followed 6 years later by a squamous carcinoma of the esophagus, N OS. Case #8 had an adenocarcinoma of the transverse colon, followed 5 years later by an adenocarcinoma of the prostate gland. Table 3 shows observed and expected numbers of bladder tumors and nonbladder tumors by estimated benzidine exposure. Only at the highest level of benzidine exposure was there a significant elevation in bladder tumor risk. There was no excess risk of all other cancers together in association with benzidine. Of the individual sites, esophagus had an excess, with 2 cases observed (0.18 expected) in men with no benzidine exposure. There were 6 lung cancers (1.65 expected) in men with medium estimated exposure. Of the 6 cases, 5 were heavy cigarette smokers. No other site had significant excess cases at any benzidine exposure level.
Length of employment was also examined in relation to incidence of bladder tumors and all nonbladder tumors. Among 460 men who worked for 0-12 months, with mean follow-up of 14. The question of whether the hygienic program adopted in and after 1950 influenced bladder tumor risk was addressed by comparison of experience of benzidineexposed men who were first employed in 1945-49 with that of those who were first employed in 1950-54. Equal length of follow-up was achieved by truncating each group after a maximum of 24 years of follow-up. There were 4 bladder tumors in the earlier group (SIR, 976; CL, 266, 2,498) and 1 in the later group (SIR, 213; CL, 5, 1,186). Note that one bladder tumor diagnosed in 1975-79 in a man who started work in 1945-49 (case #36, table 2) was omitted from this analysis because his tumor occurred more than 24 years after he started work. The mean-years of follow-up for the 180 men who started work in 1945-49 and for the 172 men in the later group were 17.1 and 16.9, respectively.
The 154 women included 5 who had ever had exposure to benzidine (2 medium, 3 high). One tumor was diagnosed in this exposed subgroup: A former secretary, who had worked over 15 years in the production area and who was classified as having had high exposure, developed thyroid cancer after retirement. Four cancers, 1 each of small intestine, gallbladder, pancreas, and breast, were diagnosed among the nonexposed women within the period of Connecticut follow-up. The overall SIR for women, based on these 5 cancers, was 87 (CL, 28, 203). An additional cancer (lung) was reported to the CTR in 1978 in a non exposed woman lost to our follow-up in 1977 and could not be included in this analysis.
DISCUSSION
This survey was designed to take maximum advantage of Connecticut data resources for both cancer ascertainment and follow-up of members of the cohort. Use of the CTR meant that we could identify essentially all cancers that were diagnosed among Connecticut residents who had ever worked at the plant under study between 1945 and 1965. This datum source was entirely independent of the company and was equally efficient for persons who had worked I day or many years. Public sources of data used for follow-up were also unbiased, so that the only possible influence of personal data from the company would have been overestimation of cancer occurrence, as noted below for bladder tumor. Availability of unbiased data for cohort members resident in Connecticut made it advantageous to include persons who worked for as short a period as 1 day.
Migration of cohort members out of the state meant loss of both person-years of follow-up and the possibility of ascertaining cancer through the CTR. This outcome reduced the power but not the validity of the study, because their cancer experiences were correctly reported up to the time of leaving Connecticut.
There was more intense follow-up for persons "everexposed" to benzidine because of the company's recall program. Thus persons with possible exposure to benzidine could have had a longer period of known Connecticut follow-up. This did not influence the ascertainment of cancer diagnoses in Connecticut for any member of the cohort, but it increased the probability that cancer diagnoses in persons with benzidine exposure could be included in analysis. This procedure was considered acceptable because it would tend to increase the probability of identifying a positive association if present. However, since follow-up was identical for all exposed persons, findings within the exposed by level of exposure should be a reasonably unbiased indication of the dose-response relationship.
Movement of workers, either within or outside of Connecticut, raises questions about possible chemical exposures at other jobs or at home, before, after, and perhaps during their employment at the company. We have no systematic information about this, although anecdotes indicated that several persons had had prior work experience with chemicals. This uncertainty about other exposures suggests caution in interpreting findings. The significant excess numbers of bladder tumors observed among men in this cohort is consistent with the histories of their exposures to benzidine. There are several questions, however, about the interpretation of these results. First, the actual numbers of cases were small, which limits statistical power of analyses that one might wish to make. Second, the 8 cases of bladder tumor included 2 that were found through urine cytology screening at presymptomatic invasive stages of disease. They were not in situ tumors. Their inclusion for statistical treatment of our data seems reasonable, but it means that our results are not precisely comparable with those of investigators who used different diagnostic criteria. Excess bladder tumors remain significant in the high-exposure group, even when these 2 cases are excluded.
The mean latent period of 20.9 years for bladder tumor among 7 men who had exposure to benzidine is consistent with reports by Case et al. (8) (18), and Tsuchiya et al. (19) . As these previous investigators had noted, there was a tendency for the latent period to be longer among men who started work at younger ages.
The attack rate for bladder tumor in our series was 7 of 597 men with a record of ever-exposed to benzidine. This rate is substantially lower than rates in most prior reports. We included all men who could have been exposed to benzidine for longer than 1 day, to search for dose-response relationships. Results (table 3) are consistent with the view that estimated level of exposure was related to outcome, with high exposure recorded in 6 of 7 cases of bladder tumor. Furthermore, the attack rate (6 of 105) among men with high exposure was within ranges noted in earlier reports.
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It seems reasonable to conclude that the excess bladder tumors observed among our cohort were attributable to occupational exposures to benzidine and that the attack rate was positively related to the dose. However, unanswerable questions remain. For example, were the benzidine-exposed workers at increased risk for cancers at sites other than in the bladder? There were no significant excess cancers of any other sites among the whole cohort of men or within subsets by estimated benzidine exposure except as noted for esophagus and lung. The esophageal cases had no history of exposure. Lung cancer cases were probably attributable to smoking. There was no dose-response relationship to benzidine exposure. A contribution of smoking to bladder tumor incidence was possible. However, since the SIR for lung cancer in those with high benzidine exposure was only 202 (CL, 41, 590), it is unlikely that the very high SIR for bladder cancer in this group is due to smoking.
Other sites with 3 or more cases (table 1) included stomach (3), colon (5), and prostate gland (5) . There was no indication that any of these cancers were associated with estimated benzidine exposure.
Other cancer sites suggested as possibly being related to benzidine exposure include the pancreas (17) and liver, gallbladder, and bile ducts (21) . No pancreatic cancers were diagnosed among benzidine-exposed workers in our study. Primary liver cancer (table 2, #13) and  extra hepatic bile duct cancer (table 2, #14) were observed. The two short employment periods, 3 weeks and 5 days, respectively, and low estimated benzidine exposures would make it difficult to attribute these cancers to the described exposures.
The question if primary kidney cancer can be induced by benzidine exposure cannot be answered from this study. One adenocarcinoma of the kidney, case #44, was observed, with 1.2 such cases expected. The kidney tumors described previously in connection with benzidine exposures (17) (18) (19) have been unspecified as to location or to histology (17) or specified as associated with the kidney pelvis and/or with ureteral and bladder tumors (18, 19) . One cannot assume that case #44 was related to prior benzidine exposure. A large series of primary adenocarcinomas of the kidney, with detailed chemical-exposure histories, would be required to develop information about this question.
The Monson program (13) that was used to analyze the data allowed us to search for effects of quinquennium for the interval between the beginning work date and latencies for all tumors, all bladder tumors, and all nonbladder tumors. No significant associations or trends, other than those already described, were identified in these analyses.
Review of information about human experience and animal studies with the substituted benzidines, dichlorobenzidine, dianisidine, and diorthotolidine does not resolve our uncertainties. No evidence for excess cancer of the bladder or at other sites has been reported among men manufacturing dichlorobenzidine for 15-30 years (22, 23) . These cohort studies were limited in size and follow-up, but both authors noted specific search for information about bladder tumors among the exposed men and found none. It seems likely that bladder cancer risks comparable with those from benzidine or l1-naphthylamine were not present at the times of these studies. Possible risks of cancers of other sites could not be evaluated from these reports. No reports of human cancers attributable to these substituted benzidines have come to our attention.
Cancers of several sites, including the liver and the bladder, have been reported in animals exposed to dichlorobenzidine (24) (25) (26) . Dianisidine and diorthotolidine have also caused animal tumors (24, 25) .
In our study, the question whether exposure to substituted benzidines could have caused bladder tumors cannot be answered with certainty. Available evidence indicates benzidine. Systematic review of benzidine production and sales records permitted preparation of a person-specific exposure estimate for benzidine, independent of total employment. This review was possible because of management concern about potential health risks of benzidine that had stimulated the hygiene program. The substituted benzidines, especially dichlorobenzidine, became the principal product of manufacture as evidence for benzidine risks became known and as its. production decreased. Accordingly, exposures to substituted benzidines are indicated more accurately by length of employment than are exposures to benzidine. If substituted benzidines caused bladder tumor, one might look for length of employment to be the best predictor of bladder tumor; but it was not.
Study of nonbladder tumors by length of employment might have indicated cancer risks from other chemicals; but it did not, either for all other cancers combined or for any individual cancer. All 3 stomach cancers occurred among men with 0-12 months employment (0.82 expected). No other significant excesses were observed for any sites or lengths of employment.
Interpretation of our results is based on .the premise that benzidine alone of these chemicals has been a human bladder carcinogen in industrial exposures. Longer follow-up will be required to either support or to refute this premise and to more fully evaluate the effects of the described hygiene program on the bladder cancer risk.
